{"id":3729,"date":"2025-04-22T16:58:45","date_gmt":"2025-04-22T13:58:45","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3729"},"modified":"2025-05-07T16:13:03","modified_gmt":"2025-05-07T13:13:03","slug":"satellos-sat-3247-phase-2-clinical-study-ready-to-launch","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/satellos-sat-3247-phase-2-clinical-study-ready-to-launch\/","title":{"rendered":"Satellos se prepara para lan\u00e7ar estudo cl\u00ednico de fase 2 do SAT-3247 para o tratamento da distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Satellos Bioscience, empresa de biotecnologia em est\u00e1gio cl\u00ednico focada no desenvolvimento de terapias regenerativas para doen\u00e7as musculares, anunciou no ClinicalTrials.Gov que est\u00e1 se preparando para iniciar um estudo cl\u00ednico de Fase 2 de seu principal candidato a medicamento, o SAT-3247, visando a Distrofia Muscular de Duchenne (DMD). Isso representa um marco significativo na miss\u00e3o da empresa de oferecer um tratamento transformador para indiv\u00edduos afetados por essa doen\u00e7a gen\u00e9tica rara e debilitante.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Estudo cl\u00ednico de fase 2 Satellos SAT-3247<\/h2><nav><ul><li class=\"\"><a href=\"#what-is-sat-3247\">O que \u00e9 SAT-3247?<\/a><\/li><li class=\"\"><a href=\"#why-this-matters-for-duchenne-muscular-dystrophy\">Por que isso \u00e9 importante para a distrofia muscular de Duchenne<\/a><\/li><li class=\"\"><a href=\"#whats-next-for-the-clinical-trial\">O que vem a seguir para o ensaio cl\u00ednico?<\/a><\/li><li class=\"\"><a href=\"#a-new-chapter-in-muscle-regeneration\">Um novo cap\u00edtulo na regenera\u00e7\u00e3o muscular<\/a><\/li><li class=\"\"><a href=\"#how-can-my-son-participate-in-the-clinical-trial\">Como meu filho pode participar do estudo cl\u00ednico de fase 2 do SAT-3247?<\/a><\/li><li class=\"\"><a href=\"#about-satellos-bioscience\">Sobre Satellos Bioscience<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sat-3247\">O que \u00e9 SAT-3247?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247 \u00e9 uma terapia de pequenas mol\u00e9culas pioneira, desenvolvida para restaurar a capacidade do corpo de regenerar m\u00fasculos, visando a polaridade das c\u00e9lulas-tronco musculares. Ao contr\u00e1rio das terapias atuais para DMD, que visam principalmente retardar a degenera\u00e7\u00e3o muscular, o SAT-3247 concentra-se na ativa\u00e7\u00e3o das vias regenerativas naturais do corpo para reconstruir e reparar o tecido muscular danificado \u2014 oferecendo uma abordagem potencialmente inovadora para a modifica\u00e7\u00e3o de doen\u00e7as.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saber mais: <a href=\"https:\/\/dmdwarrior.com\/pt\/satellos-sat-3247-stem-cell-approach-may-restore-muscle-regeneration-in-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">A abordagem com c\u00e9lulas-tronco Satellos e SAT-3247 pode restaurar a regenera\u00e7\u00e3o muscular na distrofia muscular de Duchenne<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-muscular-dystrophy\">Por que isso \u00e9 importante para a distrofia muscular de Duchenne<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A Distrofia Muscular de Duchenne \u00e9 uma doen\u00e7a gen\u00e9tica progressiva que afeta principalmente meninos, causando fraqueza muscular, perda de mobilidade e morte prematura. Os tratamentos atuais s\u00e3o limitados e muitos se concentram no controle dos sintomas, em vez de interromper ou reverter o curso da doen\u00e7a.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O lan\u00e7amento dos ensaios cl\u00ednicos de Fase 2 para o SAT-3247 \u00e9 um passo crucial para atender a essa necessidade m\u00e9dica n\u00e3o atendida. De acordo com o Satellos, o objetivo \u00e9 avaliar a seguran\u00e7a, a tolerabilidade e a efic\u00e1cia do medicamento em um grupo mais amplo de pacientes com DMD ap\u00f3s os resultados promissores da Fase 1.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"646\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg\" alt=\"Estudo cl\u00ednico de fase 2 Satellos SAT-3247\" class=\"wp-image-3735\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-300x189.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-768x485.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-666x420.jpg 666w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-150x95.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-696x439.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials.jpg 1057w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"whats-next-for-the-clinical-trial\">O que vem a seguir para o ensaio cl\u00ednico?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O estudo Satellos indicou que est\u00e1 finalizando os preparativos para a ativa\u00e7\u00e3o do local do estudo e o recrutamento de pacientes. O estudo de Fase 2 ser\u00e1 conduzido no Hospital St. Vincent, na Austr\u00e1lia, e incluir\u00e1 homens de 18 a 40 anos com diagn\u00f3stico confirmado de DMD. O estudo tamb\u00e9m avaliar\u00e1 biomarcadores de regenera\u00e7\u00e3o muscular e melhora funcional, potencialmente estabelecendo um novo padr\u00e3o no cen\u00e1rio de tratamento da Duchenne.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O Dr. Frank Gleeson, CEO da Satellos, declarou: \u201cEstamos entusiasmados em levar a SAT-3247 para a Fase 2. Esta etapa reflete nosso compromisso em ser pioneiros em uma abordagem de medicina regenerativa para Duchenne e melhorar a vida de pacientes e fam\u00edlias afetadas por esta doen\u00e7a devastadora.\u201d<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"575\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg\" alt=\"Estudo cl\u00ednico de fase 2 Satellos SAT-3247\" class=\"wp-image-3736\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-300x168.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-768x431.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-18x10.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-748x420.jpg 748w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-150x84.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-696x391.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1.jpg 1060w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Saber mais: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06867107\" target=\"_blank\" rel=\"noreferrer noopener\">Estudo cl\u00ednico de fase 2 Satellos SAT-3247: NCT06867107<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"a-new-chapter-in-muscle-regeneration\">Um novo cap\u00edtulo na regenera\u00e7\u00e3o muscular<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Com o SAT-3247, o Satellos n\u00e3o est\u00e1 apenas expandindo os limites da inova\u00e7\u00e3o cient\u00edfica, mas tamb\u00e9m levando esperan\u00e7a a milhares de fam\u00edlias em todo o mundo. Se bem-sucedida, esta terapia poder\u00e1 inaugurar uma nova classe de tratamentos regenerativos para distrofias musculares e condi\u00e7\u00f5es relacionadas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-my-son-participate-in-the-clinical-trial\">Como meu filho pode participar do estudo cl\u00ednico de fase 2 do SAT-3247?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Embora a Satellos tenha anunciado que os ensaios cl\u00ednicos de Fase 2 do SAT-3247 ser\u00e3o conduzidos na Austr\u00e1lia, recomendamos que os pacientes com DMD que tenham a oportunidade de viajar para a Austr\u00e1lia e atendam aos crit\u00e9rios entrem em contato com a Satellos usando os detalhes de contato abaixo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nome<\/strong>: : Satellos Assuntos M\u00e9dicos\/Desenvolvimento Cl\u00ednico<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de telefone<\/strong>: +61 3 8736 1750<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: medicalinfo@satellos.com<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"685\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg\" alt=\"Como meu filho pode participar do ensaio cl\u00ednico de fase 2 do SAT-3247?\" class=\"wp-image-3827\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-300x201.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-768x514.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-628x420.jpg 628w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-150x100.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-696x466.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info.jpg 1061w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"about-satellos-bioscience\">Sobre Satellos Bioscience<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A Satellos Bioscience \u00e9 uma empresa de biotecnologia sediada em Toronto, focada na descoberta e no desenvolvimento de novos medicamentos regenerativos para doen\u00e7as que envolvem degenera\u00e7\u00e3o muscular. Aproveitando sua plataforma propriet\u00e1ria MyoReGenX\u2122, a Satellos visa desvendar a biologia das c\u00e9lulas-tronco musculares para reverter a progress\u00e3o das distrofias musculares.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a clinical-stage biotechnology company focused on developing regenerative therapies for muscle diseases, has announced at ClinicalTrials.Gov it is preparing to initiate a Phase 2 clinical study of its lead drug candidate, SAT-3247, targeting Duchenne Muscular Dystrophy (DMD). This marks a significant milestone in the company\u2019s mission to offer a transformative treatment for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3739,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,254,251,252,253],"class_list":["post-3729","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=3729"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/3739"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=3729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=3729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=3729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}